

Abbas #16 - which is the same as #14

| | | | | | | | |
|--|---|----|---|------------------------------|--|----------------------------------|--|
| Subt. For, PTO-1449 | | | | Docket Number 107.823.166 | | Application Number 09/332,866 | |
| INFORMATION DISCLOSURE IN AN APPLICATION (Use several sheets if necessary) | | | | Applicant Leveugle et al. | | | |
| | | | | Filing Date June 15, 1999 | | Group Art Unit 1642 | |
| Sheet | 1 | OF | 8 | | | | |

| U.S. Patent Documents | | | | | | |
|-----------------------|--------------------|------------|------------------|-------|----------|-------------------------------|
| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| VDS ↓ | 3,865,689 | 02/11/1975 | Goldenberg | 195 | | |
| | 4,331,647 | 05/25/1982 | Goldenberg | 424 | | |
| | 5,053,224 | 10/01/1991 | Koprowski et al. | 424 | 85.8 | |
| | 5,165,922 | 11/24/1992 | Hellstrom et al. | 424 | 85.8 | |

| Foreign Patent Documents | | | | | | | |
|--------------------------|--------------------|------------|---------|-------|----------|-------------|----|
| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | YES | NO |
| VDS ↓ | 0 234 122 A2 | 09/02/1987 | EP | | | | |
| | 0 308 208 A1 | 03/22/1989 | EP | | | | |
| | WO 89/05140 | 06/15/1989 | PCT | | | | |
| | WO 88/03954 | 06/02/1988 | PCT | | | | |
| | WO 87/00053 | 01/15/1987 | PCT | | | | |

| Other Documents (Including Author, Title, Date Pertinent Pages, Etc.) | |
|---|--|
| VDS | Abbas AK et al., "Antigen presentation by B lymphocytes," <i>Antigen Presenting Cells: Diversity, Differentiation, and Regulation</i> 269-279 (1988) |
| | Adams S et al., "Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings," <i>Eur J Nucl Med.</i> 25(9):1277-83 (1998) |
| | Alzona M et al., "IL-12 activates IFN-gamma production through the preferential activation of CD30+ T cells," <i>J Immunol.</i> 154(1):9-16 (1995) |
| | American Cancer Society, "Cancer Facts and Figures," Atlanta, GA: American Cancer Society (1995) |
| | Andersson K et al., "Modulation of antigen-antibody complexations by immunoglobulins," <i>Scand J Immunol.</i> 42(4):407-17 (1995) |
| | Bachmann MF et al., "Regulation of IgG antibody titers by the amount persisting of immune-complexed antigen," <i>Eur J Immunol.</i> 24(10):2567-70 (1994) |
| | Barnd DL et al., "Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells," <i>Proc Natl Acad Sci U S A.</i> 86(18):7159-63 (1989) |
| | Bartoloni C et al., "Assay, isolation and characterization of circulating immune complexes from serum of gastrointestinal cancer, stage III and IV melanoma and chronic inflammatory bowel disease patients," <i>Oncology</i> 50(1):27-34 (1993) |
| | Bast RC Jr. et al., "A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer," <i>New England J. Med.</i> 309(15):883-7 (1983) |
| V | Baum RP et al., "Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma," <i>Cancer</i> 73(3 Suppl):1121-5 (1994) |

| | |
|--|---------------------------------|
| EXAMINER M. T. Davis | DATE CONSIDERED 02/10/02 |
| EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant. | |

| | | | | | | | |
|---|---|----|---|------------------------------|--|----------------------------------|--|
| Subt. For, PTO-1449 | | | | Docket Number 107.823.166 | | Application Number 09/332,866 | |
| INFORMATION DISCLOSURE IN AN APPLICATION <i>(Use several sheets if necessary)</i> | | | | Applicant Leveugle et al. | | | |
| | | | | Filing Date June 15, 1999 | | Group Art Unit 1642 | |
| Sheet | 2 | OF | 8 | | | | |

| | |
|--|---|
| | Bernard NF et al., "Possible Role for Specific Surface Immunoglobulin In Antigen Presentation," <i>Antigen Presenting Cells: Diversity, Differentiation, and Regulation</i> 291-300 (1988) |
| | Boon T et al., "Tumor antigens recognized by T lymphocytes," <i>Annu Rev Immunol.</i> 12:337-65 (1994) |
| | Brakenhoff RH et al., "Construction and characterization of the chimeric monoclonal antibody E48 for therapy of head and neck cancer," <i>Cancer Immunol Immunother.</i> 40(3):191-200 (1995) |
| | Bretscher PA et al., "Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to <i>Leishmania major</i> ," <i>Science</i> 257(5069):539-42 (1992) |
| | Brockmeyer NH et al., "Immunomodulation of cimetidine in healthy volunteers," <i>Klin Wochenschr.</i> 67(1):26-30 (1989) |
| | Bouige P et al., "Immune complexes as immunizing agents to increase the number of monoclonal antibody producing hybrids and to deviate the response to poorly immunogenic epitopes," <i>Hybridoma</i> 9(6):519-26 (1990) |
| | Bukowski RM et al., "Phase I trial of continuous infusion interleukin-2 and doxorubicin in patients with refractory malignancies," <i>J Immunother.</i> 10(6):432-9 (1991) |
| | Canevari S et al., "Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody," <i>J Natl Cancer Inst.</i> 87(19):1463-9 (1995) |
| | Chang CT et al., "Circular dichroic analysis of protein conformation: inclusion of the beta-turns," <i>Anal Biochem.</i> 91(1):13-31 (1978) |
| | Chatterjee MB et al., "Idiotypic antibody immunotherapy of cancer," <i>Cancer Immunol Immunother.</i> 38(2):75-82 (1994) |
| | Chester SJ et al., "Improved detection of the early stages of colon cancer by determining both free circulating and immune complex-bound antigens reactive with monoclonal antibody," <i>Cancer Res.</i> 54(15):3974-8 (1994) |
| | Cheung NK et al., "Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival," <i>Cancer Res.</i> 54(8):2228-33 (1994) |
| | Clarke-Pearson DL et al., "Palliative surgery for epithelial ovarian cancer," In Rub SC, Sutton GP eds. <i>Ovarian Cancer</i> New York: McGraw-Hill, Inc. 1993: 351-364 |
| | Crum ED, "Effect of cisplatin upon expression of in vivo immune tumor resistance," <i>Cancer Immunol Immunother.</i> 36(1):18-24 (1993) |
| | Defoin A et al., "A new liquid phase actinometer: Quantum yield and photo-cidnp study of phenylglyoxylic acid in aqueous solution," <i>J. Photochem.</i> 33:237-255 (1985) |
| | DiLeo AJ et al., "High resolution removal of virus from protein solutions using a membrane of unique structure," <i>Biotechnology</i> 10(2):182-8 (1992) |
| | DiLeo AJ et al., "Size exclusion removal of model mammalian viruses using a unique membrane system, Part II: Module qualification and process simulation," <i>Biologicals</i> 21(3):287-96 (1993) |
| | DiLeo AJ et al., "Size exclusion removal of model mammalian viruses using a unique membrane system, Part I: Membrane qualification," <i>Biologicals</i> 21(3):275-86 (1993) |

| | |
|--|---------------------|
| EXAMINER | DATE CONSIDERED |
| EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant. | |

| | | | | | |
|---|---|----|---|------------------------------|----------------------------------|
| Subt. For, PTO-1449 | | | | Docket Number 107.823.166 | Application Number 09/332,866 |
| INFORMATION DISCLOSURE IN AN APPLICATION <i>(Use several sheets if necessary)</i> | | | | Applicant Leveugle et al. | |
| | | | | Filing Date June 15, 1999 | Group Art Unit 1642 |
| Sheet | 3 | OF | 8 | | |

| | |
|------|--|
| 7/15 | Dorai, H et al., "Aglycosylated chimeric mouse/human IgG1 antibody retains some effector function," <i>Hybridoma</i> 10:211-7 (1991) |
| | Dohlsten M et al., "Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy," <i>Proc Natl Acad Sci U S A.</i> 91(19):8945-9 (1994) |
| | Dohlsten M et al., "Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo," <i>Proc Natl Acad Sci U S A.</i> 92(21):9791-5 (1995) |
| | Donnerstag B et al., "Immunological profile of patients with ovarian cancer under immunostimulation with murine monoclonal antibodies," <i>International J. of Oncology</i> 6:853-858 (1995) |
| | Durrant LG et al., "Enhanced cell-mediated tumor killing in patients immunized with human monoclonal antiidiotypic antibody 105AD7," <i>Cancer Res.</i> 54(18):4837-40 (1994) |
| | Ehrke MJ et al., "Effects of anticancer drugs on the immune system in humans," <i>Semin Oncol.</i> 16(3):230-5 (1989) |
| | Engvall E and Perlman P, "Enzyme-linked immunosorbent assay (ELISA), Quantitative assay of immunoglobulin G," <i>Immunochemistry</i> 8:871 (1971) |
| | Fagerberg J et al., "Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy?," <i>Cancer Immunol Immunother.</i> 37(4):264-70 (1993) |
| | Fagerberg J et al., "Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). II. Is induction of anti-idiotypic reactive T cells (T3) of importance for tumor response to mAb therapy?," <i>Cancer Immunol Immunother.</i> 38(3):149-59 (1994) |
| | Fagerberg J et al., "Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotypic-reactive T lymphocytes," <i>Cancer Res.</i> 55(9):1824-7 (1995) |
| | Fendrick JL et al., "Characterization of CA 125 synthesized by the human epithelial amnion WISH cell line," <i>Tumour Biol.</i> 14(5):310-8 (1993) |
| | Gadducci A et al., "Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study," <i>Gynecol Oncol.</i> 58(1):42-7 (1995) |
| | Gallagher G and Al-Azzawi F, "Adoptive immunotherapy of experimental ovarian cancer using activated human monocytes and the human monoclonal antibody, anti-14C1," <i>Int'l J of Oncology</i> 5:253-258 (1994) |
| | Gallagher G et al., "Multiple epitopes of the human ovarian cancer antigen 14C1 recognised by human IgG antibodies: their potential in immunotherapy," <i>Br J Cancer</i> 64(1):35-40 (1991) |
| | Geffner JR et al., "Activation of human neutrophils and monocytes induced by immune complexes prepared with cationized antibodies or antigens," <i>Clin Immunol Immunopathol.</i> 69(1):9-15 (1993) |
| | Goldenberg DM "New developments in monoclonal antibodies for cancer detection and therapy," <i>CA Cancer J Clin.</i> 44(1):43-64 (1994) |
| ✓ | Goronzy J et al., "Long-term humoral unresponsiveness in vivo, induced by treatment with monoclonal antibody against L3T4," <i>J Exp Med.</i> 164(3):911-25 (1986) |

| | |
|--|------------------------------------|
| EXAMINER <i>A. T. Davis</i> | DATE CONSIDERED <i>02/10/02</i> |
| EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant. | |

| | | | | | | | |
|--|---|----|---|------------------------------|--|----------------------------------|--|
| Subt. For, PTO-1449 | | | | Docket Number 107.823.166 | | Application Number 09/332,866 | |
| INFORMATION DISCLOSURE IN AN APPLICATION (Use several sheets if necessary) | | | | Applicant Leveugle et al. | | | |
| | | | | Filing Date June 15, 1999 | | Group Art Unit 1642 | |
| Sheet | 4 | OF | 8 | | | | |

| | |
|---|---|
| ✓ | Handgretinger R et al., "A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma," <i>Eur J Cancer</i> . 31A(2):261-7 (1995) |
| | Hariharan K et al., "The induction of cytotoxic T cells and tumor regression by soluble antigen formulation," <i>Cancer Res</i> . 55(16):3486-9 (1995) |
| | Harris JE and Braun DP, "Abnormal Immunoregulation and the tumor dormant state in human cancer," In: Stewart THM, Wheelock eds. <i>Cellular immune mechanisms and tumor dormancy</i> . Boca Raton, Florida: CRC Press 261-276 (1992) |
| | Hoskins PJ et al., "Ten-year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multimodality therapy," <i>J Clin Oncol</i> . 10(10):1561-8 (1992) |
| | Hozumi N and Sandhu JS, "Recombinant antibody technology: its advent and advances," <i>Cancer Invest</i> . 11(6):714-23 (1993) |
| | Hayat MA, <i>Colloidal Gold: Principles, Methods, and Applications</i> Vol. 1, San Diego: Academic Press, Inc. 1989 |
| | Ioannides CG et al., "Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides," <i>J Immunol</i> . 151(7):3693-703 (1993) |
| | Jacoby RO et al., "Characterization of mouse parvovirus infection by in situ hybridization," <i>J Virol</i> . 69(6):3915-9 (1995) |
| | Jensen JL et al., "Possible utility of serum determinations of CA 125 and CA 27.29 in breast cancer management," <i>Int. J. Biol. Markers</i> 6:1 (1991) |
| | Jerne NK, "Towards a network theory of the immune system," <i>Ann Immunol (Paris)</i> 125C(1-2):373-89 (1974) |
| | Kehoe S, "Cell-mediated immunity and immunotherapy in ovarian cancer (review)," <i>Intl J of Oncology</i> 6:451-458 (1995) |
| | Khazaeli MB et al., "Human immune response to monoclonal antibodies," <i>J Immunother</i> . 15(1):42-52 (1994) |
| | Kim HT et al., "Gamma delta T cell recognition of tumor Ig peptide," <i>J Immunol</i> . 154(4):1614-23 (1995) |
| | Knuth A et al., "T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures," <i>Proc Natl Acad Sci U S A</i> 81(11):3511-5 (1984) |
| | Kobayashi H et al., "Characterization of CA 125 antigen identified by monoclonal antibodies that recognize different epitopes," <i>Clin Biochem</i> . 26(5):391-7 (1993) |
| | Kosmas C et al., "Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer," <i>Cancer</i> 73(12):3000-10 (1994) |
| | Kosmas C et al., "Patients receiving murine monoclonal antibody therapy for malignancy develop T cells that proliferate in vitro in response to these antibodies as antigens," <i>Br J Cancer</i> 64(3):494-500 (1991) |
| | FT Kreutz and Suresh MR, "Biospecific monoclonal Anti-CA125 X Anti-peroxidase antibodies in the measurement of the ovarian carcinoma antigen," <i>J of Tumor Marker Oncology</i> 10(1):45-53 (1995) |
| ✓ | Lamers CH et al., "Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytotoxicity by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes," <i>Int J Cancer</i> 60(4):450-7 (1995) |

| | |
|--|-----------------------------|
| EXAMINER M. T. Davis | DATE CONSIDERED 02/06/02 |
| EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant. | |

| | | | | | | | |
|--|---|----|---|------------------------------|--|----------------------------------|--|
| Subl. For, PTO-1449 | | | | Docket Number 107.823.166 | | Application Number 09/332,866 | |
| INFORMATION DISCLOSURE IN AN APPLICATION (Use several sheets if necessary) | | | | Applicant Leveugle et al. | | | |
| | | | | Filing Date June 15, 1999 | | Group Art Unit 1642 | |
| Sheet | 5 | OF | 8 | | | | |

| | |
|-------------------------------------|---|
| <input checked="" type="checkbox"/> | Lanzavecchia A, "Identifying strategies for immune intervention," <i>Science</i> 260(5110):937-44 (1993) |
| <input type="checkbox"/> | Lanzavecchia A et al., "Antibodies as antigens. The use of mouse monoclonal antibodies to focus human T cells against selected targets," <i>J Exp Med.</i> 167(2):345-52 (1988) |
| <input type="checkbox"/> | Livingston Po et al., "Sympsoium 10: glucosylation defining malignancy. Effect of active immunization with human tumor associated carbohydrate antigens on the immune response and on tumor growth," <i>Proc. Am. Assoc. Cancer Research</i> 36:678 (1995) |
| <input type="checkbox"/> | Loevinger, RL et al., <u>MIRD Primer for Absorbed Dose Calculations</u> New York: Society of Nuclear Medicine, 1991 <i>page ?</i> |
| <input type="checkbox"/> | Lopes LM and Chain BM, "Liposome-mediated delivery stimulates a class I-restricted cytotoxic T cell response to soluble antigen," <i>Eur J Immunol.</i> 22(1):287-90 (1992) |
| <input type="checkbox"/> | Madiyalakan R et al., "Antiidiotype induction therapy: evidence for the induction of immune response through the idiotypic network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13," <i>Hybridoma</i> 14(2):199-203 (1995) |
| <input type="checkbox"/> | Manca F et al., "Effect of antigen/antibody ratio on macrophage uptake, processing, and presentation to T cells of antigen complexed with polyclonal antibodies," <i>J Exp Med.</i> 173(1):37-48 (1991) |
| <input type="checkbox"/> | Maraveyas A and Epenetos AA, "Targeted immunotherapy. An update with special emphasis on ovarian cancer," <i>Acta Oncol.</i> 32(7-8):741-6 (1993) |
| <input type="checkbox"/> | Martin AC et al., "Modeling antibody hypervariable loops: a combined algorithm," <i>Proc Natl Acad Sci U S A</i> 86:9268-72 (1986) |
| <input type="checkbox"/> | Marusic-Galesic S et al., "Cellular immune response to the antigen administered as an immune complex," <i>Immunology.</i> 72(4):526-31 (1991) |
| <input type="checkbox"/> | Meier W, "CA 125 based diagnosis and therapy in recurrent ovarian cancer," Abstract. <i>Abstracts of the Eighth International Hamburg Symposium on Tumor Markers</i> Hamburg, Germany 2443 (1995) |
| <input type="checkbox"/> | Mitchell MS, <u>Biological Approaches to Cancer Treatment: Biomodulation</u> New York: McGrawHill, Inc., 1993 |
| <input type="checkbox"/> | Mitchell MS et al., "Biomodulators in cancer treatment," <i>J Clin Pharmacol.</i> 32(1):2-9 (1992) |
| <input type="checkbox"/> | Mosmann TR and RL Coffman, "Two types of mouse helper t-cell clone, Review. <i>Immunology Today</i> 8(7 and 8):223-227 (1987) |
| <input type="checkbox"/> | Muddukrishna SN et al., "Indirect iodometric procedure for quantation of Sn(II) in radiopharmaceutical kits," <i>Appl. Radial. Isot.</i> 45(3):293-299 (1994) |
| <input type="checkbox"/> | Munn DH and Cheung NK "Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma," <i>Cancer Res.</i> 47(24 Pt 1):6600-5 (1987) |
| <input type="checkbox"/> | Naramura M et al., "Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma," <i>Cancer Immunol Immunother.</i> 37(5):343-9 (1993) |
| <input type="checkbox"/> | National Cancer Institute of Canada, "Canadian Cancer Statistics" Toronto: National Cancer Institute of Canada (1998) <i>page ?</i> |
| <input checked="" type="checkbox"/> | Nemazee DA and Sato VL, "Enhancing antibody: a novel component of the immune response," <i>Proc Natl Acad Sci U S A.</i> 79(12):3828-32 (1982) |

| | |
|--|------------------------------------|
| EXAMINER <i>M. T. Davis</i> | DATE CONSIDERED <i>02/10/02</i> |
| EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant. | |

| | | | | | |
|---|---|----|---|------------------------------|----------------------------------|
| Subl. For, PTO-1449 | | | | Docket Number 107.823.166 | Application Number 09/332,866 |
| INFORMATION DISCLOSURE IN AN APPLICATION <i>(Use several sheets if necessary)</i> | | | | Applicant Leveugle et al. | |
| | | | | Filing Date June 15, 1999 | Group Art Unit 1642 |
| Sheet | 6 | OF | 8 | | |

| | | |
|---|---|---|
| 1 | ✓ | Ohta S et al., "Tumor-associated glycoantigen, sialyl Lewis ^a as a target for bispecific antibody-directed adoptive tumor immunotherapy," <i>Immunol Lett.</i> 44(1):35-40 (1995) |
| | | Ovarian Cancer: Screening, Treatment, and Followup. NIH Consens Statement 12(3):1-30 (1994) |
| | | Ozols, MD, PhD, RF "Biologic Treatment of Human Cancer," <i>Current Problems in Cancer</i> 19(4):186-261 (1995) |
| | | Pederson J et al., "Antibody Modeling: Beyond Homology," <i>Immunomethods</i> 1:126-136 (1992) |
| | | Perala-Heape M et al., "Effects of tumour mass and circulating antigen on the biodistribution of 111In-labelled F(ab') ₂ fragments of human prostatic acid phosphatase monoclonal antibody in nude mice bearing PC-82 human prostatic tumour xenografts," <i>Eur J Nucl Med.</i> 18(5):339-45 (1991) |
| | | Pierce SK and LA Casten, "Soluble globular protein antigens covalently coupled to antibodies specific for b cell surface structures are effective antigens both in vitro and in vivo," <i>Antigen presenting cells: diversity, differentiation, and regulation</i> 259-268 (1988) |
| | | Pimm MV, "Circulating antigen: bad or good for immunoscintigraphy?" <i>Nucl Med Biol.</i> 22(2):137-45. Review. (1995) |
| | | Pimm MV et al., "Influence of syngeneic monoclonal anti-idiotypic antibodies to murine monoclonal antibodies against tumour-associated antigens on the biodistribution of their target antibodies and their fragments," <i>J Cancer Res Clin Oncol.</i> 119(7):408-14 (1993) |
| | | Pimm MV and Gribben SJ, "Toxicity associated with the formation and clearance of immune complexes between antitumour monoclonal antibodies and syngeneic anti-idiotypic antibodies in mice," <i>J Cancer Res Clin Oncol.</i> 119(1):41-5 (1992) |
| | | Provencher SW and Glockner J, "Estimation of globular protein secondary structure from circular dichroism," <i>Biochemistry</i> 20(1):33-7 (1981) |
| | | Randall RE et al., "Purification of antibody-antigen complexes containing recombinant SIV proteins: comparison of antigen and antibody-antigen complexes for immune priming," <i>Vaccine</i> 12(4):351-8 (1994) |
| | | Riethmuller G et al., "Monoclonal antibodies in cancer therapy," <i>Curr Opin Immunol.</i> 5(5):732-9 (1993) |
| | | Riethmuller G et al., "Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma," <i>Lancet</i> 343(8907):1177-83 (1994) |
| | | Ron IG et al., "Use of CA-125 response to predict survival parameters of patients with advanced ovarian carcinoma," <i>Acta Obstet Gynecol Scand.</i> 73(8):658-62 (1994) |
| | | Roosnek E and A Lanzavecchia, "Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells," <i>J Exp Med.</i> 173(2):487-9 (1991) |
| | | Schlebusch H et al., "A monoclonal antiidiotypic antibody ACA 125 mimicking the tumor-associated antigen CA 125 for immunotherapy of ovarian cancer," <i>Hybridoma</i> 14(2):167-7 (1995) |
| | ✓ | Schmolling J et al., "Antiidiotypic antibodies in ovarian cancer patients treated with the monoclonal antibody B72.3," <i>Hybridoma</i> 14(2):183-6 (1995) |

| | |
|--|---------------------------------|
| EXAMINER M. T. Davis | DATE CONSIDERED 02/10/02 |
| EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant. | |

| | | | | | |
|---|---|----|---|------------------------------|----------------------------------|
| Subt. For, PTO-1449 | | | | Docket Number 107.823.166 | Application Number 09/332,866 |
| INFORMATION DISCLOSURE IN AN APPLICATION <i>(Use several sheets if necessary)</i> | | | | Applicant Leveugle et al. | |
| | | | | Filing Date June 15, 1999 | Group Art Unit 1642 |
| Sheet | 7 | OF | 8 | | |

| | |
|-------------------------------------|---|
| <input checked="" type="checkbox"/> | Schultes BC et al., "Idiotypic cascades after injection of the monoclonal antibody OC125: a study in a mouse model. Induction of antibodies against OC125 and CA125 after immunization with an anti-CA 125 (MAb OC125) monoclonal antibody by activation of the idiotype network," <i>Eur J Clin Chem Clin Biochem.</i> 31(7):427-32 (1993) |
| <input type="checkbox"/> | Sciammas R et al., "TCR gamma delta cells: mysterious cells of the immune system," <i>Immunol Res.</i> 13(4):268-79 (1994) |
| <input type="checkbox"/> | Shitara K et al., "A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced antitumor activities," <i>Cancer Immunol Immunother.</i> 36(6):373-80 (1993) |
| <input type="checkbox"/> | Snyder et al., <u>A Tabulation of Dose Equivalent per Microcurie-Day for Source and Target Organs of an Adult for Various Radionuclides</u> Oak Ridge National Laboratory, Oak Ridge Tn (1975) <i>page ?</i> |
| <input type="checkbox"/> | Spalding BJ, "Few firms pursue anti-ids," <i>Bio/Technology</i> 10:950 (1992) |
| <input type="checkbox"/> | Squire CM et al., "Antigen presentation is enhanced by targeting antigen to the Fc epsilon RII by antigen-anti-Fc epsilon RII conjugates," <i>J Immunol.</i> 152(9):4388-96 (1994) |
| <input type="checkbox"/> | Stevenson FK and RE Hawkins, "Molecular Vaccines Against Cancer," <i>Immunologist</i> 2(1):16-19 (1994) |
| <input type="checkbox"/> | Strieter RM et al., "Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline," <i>Biochem Biophys Res Commun.</i> 155(3):1230-6 (1988) |
| <input type="checkbox"/> | Sulica A et al., "Regulation of human natural cytotoxicity by IgG. IV. Association between binding of monomeric IgG to the Fc receptors on large granular lymphocytes and inhibition of natural killer (NK) cell activity," <i>Cell Immunol.</i> 147(2):397-410 (1993) |
| <input type="checkbox"/> | Taggart, RT, Samloff IM., "Stable antibody-producing murine hybridomas," <i>Science</i> 219:1228-1230 (1983) |
| <input type="checkbox"/> | Tew JG et al., "Induction of the secondary antibody response: immune complex formation, iccosome release by follicular dendritic cells, processing and presentation of antigen by germinal center b cells and tingible body macrophages," <i>Progress in Leukocyte Biology</i> 7:1-10 Alan R Liss, Inc., New York (1988) |
| <input type="checkbox"/> | Thomson AW and JV Forrester, "Therapeutic advances in immunosuppression," <i>Clin Exp Immunol.</i> 98(3):351-7 (1994) |
| <input type="checkbox"/> | Torbett BE et al., "hu-PBL-SCID mice: a model for human immune function, AIDS, and lymphomagenesis," <i>Immunol Rev.</i> 124:139-64 (1991) |
| <input type="checkbox"/> | Trauth BC et al., "Monoclonal antibody-mediated tumor regression by induction of apoptosis," <i>Science</i> 245(4915):301-5 (1989) |
| <input type="checkbox"/> | Ullman EF et al., "Anti-immune complex antibodies enhance affinity and specificity of primary antibodies," <i>Proc Natl Acad Sci U S A.</i> 90(4):1184-9 (1993) |
| <input type="checkbox"/> | United Nations, Demographic Yearbook, 1992 Forty-fourth issue, New York (1994) <i>page ?</i> |
| <input type="checkbox"/> | United Nations Population Fund, The State of World Population, 1991 <i>page ?</i> |
| <input type="checkbox"/> | van der Bruggen P, "The long-standing quest for tumor rejection antigens," <i>Clin Immunol Immunopathol</i> 71(3):248-52 (1994) |
| <input checked="" type="checkbox"/> | Vitetta ES and JW Uhr, "Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy," <i>Cancer Res.</i> 54(20):5301-9 (1994) |

| | |
|--|------------------------------------|
| EXAMINER <i>M. T. Davis</i> | DATE CONSIDERED <i>02/10/02</i> |
| EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant. | |

| | | | | | |
|--|---|----|---|------------------------------|----------------------------------|
| Subt. For, PTO-1449 | | | | Docket Number 107.823.166 | Application Number 09/332,866 |
| INFORMATION DISCLOSURE IN AN APPLICATION (Use several sheets if necessary) | | | | Applicant Leveugle et al. | |
| | | | | Filing Date June 15, 1999 | Group Art Unit 1642 |
| Sheet | 8 | OF | 8 | | |

| | |
|--|---|
| | Vose BM and Bonnard GD, "Specific cytotoxicity against autologous tumour and proliferative responses of human lymphocytes grown in interleukin 2," <i>Int J Cancer</i> 29(1):33-9 (1982) |
| | Wagner U, "Antitumor antibodies for immunotherapy of ovarian carcinomas," <i>Hybridoma</i> 12(5):521-8 (1993) |
| | Wagner U et al., "Clinical courses of patients with ovarian carcinomas after induction of anti-idiotypic antibodies against a tumor-associated antigen," <i>Tumor Diagnostic & Therapeutic</i> 11:1-4 (1990) |
| | Wagner UA et al., "Immunotherapy of advanced ovarian carcinomas by activation of the idiotypic network," <i>Biotechnol Ther.</i> 3(1-2):81-9 (1992) |
| | Walker AM et al., "Prolactin-immunoglobulin G complexes from human serum act as costimulatory ligands causing proliferation of malignant B lymphocytes," <i>Proc Natl Acad Sci U S A.</i> 92(8):3278-82 (1995) |
| | Wawrzynczak EJ et al., "Blood clearance in the rat of a recombinant mouse monoclonal antibody lacking the N-linked oligosaccharide side chains of the CH2 domains," <i>Mol Immunol.</i> 29:213-20 (1992) |
| | Weber D, MIRD: Radiocluclide Data and Decay Schemes New York: Society of Nuclear Medicine, 1989 <i>119?</i> |
| | Wiersma EJ et al., "Enhancement of the antibody response to protein antigens by specific IgG under different experimental conditions," <i>Scand J Immunol.</i> 36(2):193-200 (1992) |
| | Wolff EA et al., "Monoclonal antibody homodimers: enhanced antitumor activity in nude mice," <i>Cancer Res.</i> 53(11):2560-5 (1993) |
| | Wyatt, PJ "Light scattering and the absolute characterization of macromolecules" Review. <i>Analytica Chimica Acta</i> 272:1-40 (1993) |
| | Xu ZY et al., "Overcoming suppression of antitumor immune reactivity in tumor-bearing rats by treatment with bleomycin," <i>Cancer Res.</i> 48(23):6658-63 (1988) |
| | Yano S et al., "Natural antibodies against the immunoglobulin F(ab')2 fragment cause elimination of antigens recognized by the F(ab')2 from the circulation," <i>Eur J Immunol.</i> 25(11):3128-33 (1995) |
| | Zhang S et al., "Increased tumor cell reactivity and complement-dependent cytotoxicity with mixtures of monoclonal antibodies against different gangliosides," <i>Cancer Immunol Immunother.</i> 40(2):88-94 (1995) |

diana havens - h:\chiu_nancy\legal\docs\altarex\107823.166\altarexids 166.doc

| | |
|--|------------------------------------|
| EXAMINER <i>M. T. Davis</i> | DATE CONSIDERED <i>02/10/02</i> |
| EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant. | |